Výsledky vyhledávání - "Joseph J Lynch"

Akademický článek

Effects of carvedilol on structural and functional outcomes and plasma biomarkers in the mouse transverse aortic constriction heart failure model

Autor: Caryn Hampton, Raymond Rosa, Daphne Szeto, Gail Forrest, Barry Campbell, Richard Kennan, Shubing Wang, Chin-Hu Huang, Loise Gichuru, Xiaoli Ping, Xiaolan Shen, Kersten Small, Jeffrey Madwed, Joseph J Lynch

Publikováno v: SAGE Open Medicine, Vol 5 (2017)

Introduction: Despite the widespread use of the mouse transverse aortic constriction heart failure model, there are no reports on the characterization of the standard-of-care agent carvedilol in this model. Methods: Left ventricular pressure overload

Externí odkaz: https://doaj.org/article/f63b2f7ff471419f8b3ad093784171db

Zobrazit plný text záznamu

Early echocardiographic predictors of outcomes in the mouse transverse aortic constriction heart failure model

Autor: Kersten M. Small, Caryn Hampton, Loise Gichuru, Joseph J. Lynch, Xiaoli Ping, Ray Rosa, Richard Kennan, Jeffrey B. Madwed, Xiaolan Shen, Barry R. Campbell

Publikováno v: Journal of Pharmacological and Toxicological Methods. 84:93-101

Introduction Mouse transverse aortic constriction (TAC) is a widely-used model of pressure overload-induced heart failure. An intrinsic limitation of the model is variability in the response to pressure overload even when employing a standard severit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6727b68ed4cd0d8e428f81c3429ec1eb
https://doi.org/10.1016/j.vascn.2016.12.001

Zobrazit plný text záznamu

Interconnect and Packaging Techniques for System Integration of High Power Assemblies that Improve Assembly Efficiency and Design Flexibility

Autor: Joseph J. Lynch, Richard Schneider, Andy Longford

Publikováno v: International Symposium on Microelectronics. 2014:000763-000768

Growth in electrification and power conversion is driving a large need for electrical efficiency and improved cost models that in theory can be gained through the design consolidation of secondary assemblies into complete single modules. To put this

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::662bf960481f72be7f4623e258a4419a
https://doi.org/10.4071/isom-wp55

Zobrazit plný text záznamu

Enantioselective Synthesis of a Highly Substituted Tetrahydrofluorene Derivative as a Potent and Selective Estrogen Receptor Beta Agonist

Publikováno v: Organic Process Research & Development. 18:528-538

The development and execution of a practical asymmetric synthesis of the estrogen receptor beta selective agonist (8R,10aS)-6-(trifluoromethyl)-8,9,10,11-tetrahydro-8,10a-methanocyclohepta[1,2]indeno[4,5-d][1,2,3]triazol-7(3H)-one is described. The o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fdefbcc65171430752e7a0100c3ac289
https://doi.org/10.1021/op5000489

Zobrazit plný text záznamu

Practical and Cost-Effective Manufacturing Route for the Synthesis of a β-Lactamase Inhibitor

Autor: Yong-Li Zhong, Zheng Chen, Joseph J. Lynch, John Limanto, Michael Simeone, Steven P. Miller, Zhijian Liu, Nobuyoshi Yasuda, Vincent R. Capodanno

Publikováno v: Organic Letters. 16:174-177

Compound 1, a potent and irreversible inhibitor of β-lactamases, is in clinical trials with β-lactam antibiotics for the treatment of serious and antibiotic-resistant bacterial infections. A short, scalable, and cost-effective route for the product

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db907311ee6b30675186703892fd8b27
https://doi.org/10.1021/ol4031606

Zobrazit plný text záznamu

Comparison of the Intrinsic Vasorelaxant and Inotropic Effects of the Antiarrhythmic Agents Vernakalant and Flecainide in Human Isolated Vascular and Cardiac Tissues

Autor: Gilbert W. Gleim, Christopher J. Morabito, Joseph J. Lynch, Gregory N. Beatch, Christopher P. Regan

Publikováno v: Journal of Cardiovascular Pharmacology. 61:226-232

This study explored the intrinsic vasorelaxant and inotropic effects of the mixed potassium and sodium channel blocker atrial antiarrhythmic vernakalant and the class IC antiarrhythmic agent flecainide in human isolated subcutaneous resistance artery

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10adadd23d92658554b07cd609b79a2e
https://doi.org/10.1097/fjc.0b013e31827afd29

Zobrazit plný text záznamu

The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation

Autor: Nadiia Rozmaritsa, Michael Knaut, John K. Gibson, Torsten Christ, Marc Pourrier, David Fedida, Klaus Matschke, Erich Wettwer, Joseph J. Lynch, Sebastian Endig, Ursula Ravens

Publikováno v: Cardiovascular Research. 98:145-154

Aims Vernakalant is a newly developed antiarrhythmic drug against atrial fibrillation (AF). However, its electrophysiological actions on human myocardium are unknown. Methods and results Action potentials (APs) and ion currents were recorded in right

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58f90a50ba9866599050022294c63924
https://doi.org/10.1093/cvr/cvt006

Zobrazit plný text záznamu

Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics

Publikováno v: Bioorganicmedicinal chemistry letters. 27(4)

Selective inhibition of Kv1.5, which underlies the ultra-rapid delayed rectifier current, IKur, has been pursued as a treatment for atrial fibrillation. Here we describe the discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity versus the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c28d78944ff68aea790d3850958003ea
https://pubmed.ncbi.nlm.nih.gov/28131713

Zobrazit plný text záznamu

Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations

Autor: John K. Gibson, Charles Antzelevitch, Joseph J. Lynch, Serge Sicouri, Marc Pourrier

Publikováno v: Heart Rhythm. 9:422-429

Background Vernakalant (VER) is a relatively atrial-selective antiarrhythmic drug capable of blocking potassium and sodium currents in a frequency- and voltage-dependent manner. Ranolazine (RAN) is a sodium-channel blocker shown to exert antiarrhythm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37208610b67ec07c4bb76a63bed8b7ad
https://doi.org/10.1016/j.hrthm.2011.10.021

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání